DCT
1:22-cv-01190
Biogen Inc v. Sandoz Inc
Key Events
Amended Complaint
Table of Contents
complaint Intelligence
I. Executive Summary and Procedural Information
- Parties & Counsel:
- Plaintiff: Biogen Inc. (Delaware) and Biogen MA Inc. (Massachusetts)
- Defendant: Sandoz Inc. (Delaware)
- Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
- Case Identification: 1:22-cv-01190, D. Del., 02/03/2026
- Venue Allegations: Venue is alleged to be proper as Defendant Sandoz Inc. is a Delaware corporation and is subject to personal jurisdiction in the district. The complaint notes Sandoz has purposefully directed activities in Delaware and has not contested venue.
- Core Dispute: Plaintiff alleges that Defendant's marketing and distribution of its biosimilar natalizumab product, Tyruko, along with an associated patient-support testing program, indirectly infringes two patents covering methods of using anti-JCV antibody testing to improve the safety of natalizumab treatment.
- Technical Context: The technology concerns risk management for patients taking natalizumab (Tysabri®), a highly effective therapy for multiple sclerosis and Crohn's disease that carries a risk of progressive multifocal leukoencephalopathy (PML), a rare and often fatal brain infection linked to the John Cunningham virus (JCV).
- Key Procedural History: This action arises under the Biologics Price Competition and Innovation Act (BPCIA) following Sandoz's submission of an abbreviated Biologics License Application (aBLA) for Tyruko, a biosimilar of Biogen's Tysabri®. The complaint states the parties engaged in the BPCIA's pre-litigation information exchange, during which Biogen identified the patents-in-suit. Biogen's Tysabri® was voluntarily withdrawn from the market in 2005 due to PML cases and re-introduced in 2006 with a risk management program that included the development of an anti-JCV antibody test to stratify patient risk.
Case Timeline
| Date | Event |
|---|---|
| 2004-11-01 | Tysabri first approved by FDA for Multiple Sclerosis (MS). |
| 2005-02-28 | Biogen voluntarily withdraws Tysabri from the market due to PML cases. |
| 2006-02-28 | Priority date for U.S. Patent Nos. 10,233,245 and 11,292,845. |
| 2006-06-05 | Tysabri re-approved by FDA for re-entry to the market. |
| 2007-02-28 | First non-provisional application filed for the '245 and '845 patents. |
| 2008-01-01 | Tysabri approved by FDA for treatment of moderate to severe Crohn's Disease. |
| 2019-03-19 | U.S. Patent No. 10,233,245 ("the '245 patent") issues. |
| 2019-09-02 | Sandoz allegedly collaborates with Polpharma to develop an anti-JCV antibody assay. |
| 2022-04-05 | U.S. Patent No. 11,292,845 ("the '845 patent") issues. |
| 2022-06-27 | Sandoz contacts Biogen to initiate BPCIA pre-litigation information exchanges. |
| 2022-07-25 | FDA accepts Sandoz's aBLA for its biosimilar, Tyruko. |
| 2023-08-24 | FDA approves Sandoz's Tyruko. |
| 2025-11-17 | Sandoz allegedly begins offering Tyruko for sale in the United States. |
| 2026-02-03 | Biogen files Third Amended Complaint. |
II. Technology and Patent(s)-in-Suit Analysis
U.S. Patent No. 10,233,245 - "Methods Of Treating Inflammatory And Autoimmune Diseases With Natalizumab"
- Patent Identification: U.S. Patent No. 10,233,245, titled "Methods Of Treating Inflammatory And Autoimmune Diseases With Natalizumab," issued March 19, 2019 Compl. ¶60
The Invention Explained
- Problem Addressed: The administration of natalizumab (Tysabri®), a treatment for diseases like multiple sclerosis, carries a significant risk of Progressive Multifocal Leukoencephalopathy (PML), a severe brain infection associated with the John Cunningham virus (JCV) Compl. ¶¶36-38 '245 Patent, col. 3:15-22 A key challenge was identifying which patients were at a higher risk of developing this potentially fatal side effect Compl. ¶48
- The Patented Solution: The patent discloses a method to enhance the safety of natalizumab treatment by first assessing a patient's risk profile. This is accomplished by testing a patient's blood sample for the presence or absence of antibodies to the JC virus (anti-JCV antibodies) '245 Patent, abstract A negative result for anti-JCV antibodies indicates a lower risk of developing PML, thereby identifying a patient population for whom initiating natalizumab treatment presents a more favorable risk-benefit profile '245 Patent, col. 5:1-12
- Technical Importance: This risk stratification method was a key innovation that enabled the safe and widespread use of natalizumab, a highly effective therapy, by allowing physicians to make more informed treatment decisions based on a patient's individual PML risk profile Compl. ¶¶43, 52
Key Claims at a Glance
- The complaint asserts independent claim 1 and notes its right to assert others, including dependent claim 2 Compl. ¶¶129, 131, 146
- Representative claim 1 of the '245 patent recites:
- A method of using natalizumab to treat a patient with an inflammatory or autoimmune disease, the method comprising:
- (a) testing the patient for the presence of anti-JC virus (JCV) antibodies by a method consisting of determining a presence or absence of anti-JCV antibodies in serum or plasma of a blood sample of a patient;
- (b) identifying the patient as having serum or plasma that is negative for anti-JCV antibodies; and
- (c) initiating natalizumab treatment of the patient having serum or plasma that is negative for anti-JCV antibodies, wherein the testing of (a) improves the safety of the natalizumab treatment Compl. ¶129
U.S. Patent No. 11,292,845 - "Methods Of Treating Inflammatory And Autoimmune Diseases With Natalizumab"
- Patent Identification: U.S. Patent No. 11,292,845, titled "Methods Of Treating Inflammatory And Autoimmune Diseases With Natalizumab," issued April 5, 2022 Compl. ¶61
The Invention Explained
- Problem Addressed: As with the '245 patent, the invention addresses the risk of PML associated with natalizumab therapy Compl. ¶¶36-38 '845 Patent, col. 3:15-22 This patent extends beyond the initial risk assessment to address how risk can change and be managed over the full course of treatment.
- The Patented Solution: The patent describes a method for improving treatment safety by continuously monitoring the patient after natalizumab administration '845 Patent, abstract The monitoring involves periodically testing the patient's blood to detect "seroconversion" (a change from anti-JCV antibody negative to positive) or an "increasing titer" of anti-JCV antibodies, which indicate a heightened risk of PML '845 Patent, col. 3:27-31 The method includes discontinuing treatment if these risk indicators are present, thereby improving the overall safety of the therapy '845 Patent, col. 3:32-35
- Technical Importance: This method provides a framework for dynamic risk management throughout a patient's treatment course, allowing for therapy to be adjusted or stopped if a patient's PML risk profile elevates over time Compl. ¶¶62, 158
Key Claims at a Glance
- The complaint asserts independent claim 1 and notes its right to assert others, including dependent claim 15 Compl. ¶¶153, 155, 171
- Representative claim 1 of the '845 patent recites:
- A method of using natalizumab to treat a patient with an inflammatory or autoimmune disease comprising:
- (a) administering a pharmaceutically effective amount of natalizumab to the patient;
- (b) monitoring the patient for indicators of progressive multifocal leukoencephalopathy (PML), wherein the monitoring comprises detecting seroconversion and/or an increasing titer of JC virus (JCV) antibodies in the patient's blood; and
- (c) discontinuing the administration of natalizumab in the presence of seroconversion and/or an increasing titer of JCV antibodies; wherein the monitoring improves the safety of the treatment Compl. ¶153
III. The Accused Instrumentality
Product Identification
- The accused instrumentalities are Sandoz's biosimilar natalizumab product, Tyruko®, and the associated "Tyruko JCV Testing Program" Compl. ¶¶3, 6, 85
Functionality and Market Context
- Tyruko is a biosimilar version of Biogen's Tysabri® product, approved for the same indications of treating relapsing forms of Multiple Sclerosis and Crohn's Disease Compl. ¶¶3, 76
- Sandoz provides Tyruko through a Risk Evaluation and Mitigation Strategy (REMS) program that warns of PML risk and is designed to inform prescribers and patients about this risk Compl. ¶84
- In conjunction with its product, Sandoz has partnered with Laboratory Corporation of America Holdings ("Labcorp") to offer the "Tyruko JCV Testing Program" Compl. ¶85 This program provides healthcare providers with a laboratory-developed test (LDT) to detect and monitor the presence of anti-JCV antibodies in patients Compl. ¶¶85-87
- The complaint alleges that the Tyruko product label, REMS program materials, and associated websites instruct and encourage healthcare providers to test for anti-JCV antibodies before and during treatment with Tyruko to manage PML risk Compl. ¶¶134, 158
- No probative visual evidence provided in complaint.
IV. Analysis of Infringement Allegations
U.S. Patent No. 10,233,245 Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| (a) testing the patient for the presence of anti-JC virus (JCV) antibodies by a method consisting of determining a presence or absence of anti-JCV antibodies in serum or plasma of a blood sample of a patient; | Sandoz, in partnership with Labcorp, offers the "Tyruko JCV Testing Program," which provides an LDT for detecting anti-JCV antibodies. The Tyruko label and associated materials allegedly instruct and encourage this testing. | ¶¶85-87; ¶134; ¶140 | col. 5:1-6 |
| (b) identifying the patient as having serum or plasma that is negative for anti-JCV antibodies; and | The Tyruko label allegedly instructs that an "anti-JCV antibody negative status indicates that antibodies to the JC virus have not been detected," thereby identifying this patient sub-group. | ¶79; ¶136 | col. 5:6-8 |
| (c) initiating natalizumab treatment of the patient having serum or plasma that is negative for anti-JCV antibodies, wherein the testing of (a) improves the safety of the natalizumab treatment. | The complaint alleges that the Tyruko label and REMS program, by highlighting the lower risk of PML for antibody-negative patients, encourage initiating treatment in this population to improve safety. | ¶134; ¶136-137 | col. 5:8-12 |
- Identified Points of Contention:
- Scope Questions: A central question may be whether Sandoz's actions-providing a drug, a label with risk information, and a testing program-constitute inducement to infringe a method claim. Sandoz may argue that it only provides tools and information, while the decision to perform the claimed steps of testing, identifying, and initiating treatment remains the independent medical judgment of the prescribing physician.
- Technical Questions: The analysis may focus on whether the instructions and materials provided by Sandoz rise to the level of directing or encouraging the specific sequence of steps required by the claim, particularly the step of "initiating" treatment specifically in anti-JCV negative patients, as opposed to merely providing information for a physician's overall risk-benefit analysis.
U.S. Patent No. 11,292,845 Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| (a) administering a pharmaceutically effective amount of natalizumab to the patient; | The Tyruko label instructs administering a "300 mg intravenous infusion over one hour every four weeks," which is alleged to be a pharmaceutically effective amount. | ¶160 | col. 3:36-39 |
| (b) monitoring the patient for indicators of progressive multifocal leukoencephalopathy (PML), wherein the monitoring comprises detecting seroconversion and/or an increasing titer of JC virus (JCV) antibodies in the patient's blood; and | The Tyruko label and associated materials allegedly instruct prescribers to periodically retest patients to monitor for changes in anti-JCV antibody status, including seroconversion, which the label notes occurs at a rate of 3 to 8 percent annually. | ¶158; ¶161 | col. 3:27-31 |
| (c) discontinuing the administration of natalizumab in the presence of seroconversion and/or an increasing titer of JCV antibodies; wherein the monitoring improves the safety of the treatment. | The complaint alleges the Tyruko label instructs providers to consider the risk of PML and to "[w]ithhold TYRUKO dosing immediately" at the first sign of PML, which, in the context of the entire risk management scheme, allegedly instructs discontinuing treatment upon an increase in risk factors like antibody titer. | ¶158; ¶162; ¶163 | col. 3:32-35 |
- Identified Points of Contention:
- Scope Questions: As with the '245 patent, a primary dispute may be whether Sandoz's materials actively induce infringement or merely inform physicians, who then exercise independent medical judgment.
- Technical Questions: A significant point of contention may be the "discontinuing" step. The complaint quotes the Tyruko label as instructing to withhold dosing "at the first sign or symptom suggestive of PML" Compl. ¶162 Sandoz may argue this is different from the claim's requirement to discontinue "in the presence of seroconversion and/or an increasing titer," as a change in antibody status alone, without clinical symptoms, does not trigger a direct instruction to discontinue.
V. Key Claim Terms for Construction
'245 Patent, Claim 1: "improves the safety of the natalizumab treatment"
- Context and Importance: This "wherein" clause describes the purpose and result of the claimed method. Its construction is critical because it defines a required outcome of the testing step. Practitioners may focus on this term to dispute whether it is an enforceable limitation or a mere statement of intended use, and what level of proof is required to show that the accused testing program "improves... safety."
- Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The patent specification repeatedly frames the invention in the context of improving safety and managing PML risk, suggesting any testing that facilitates risk stratification meets this limitation '245 Patent, col. 1:21-22 '245 Patent, col. 5:11-12
- Evidence for a Narrower Interpretation: A defendant could argue the term is indefinite without a specific benchmark for what constitutes an "improvement" in safety. The specification also discusses specific risk probabilities and index values, which could be argued to set a higher, more quantitative standard for "improving safety" than merely offering a test '245 Patent, col. 2:37-43
'845 Patent, Claim 1: "discontinuing...in the presence of seroconversion and/or an increasing titer"
- Context and Importance: This term is the central action step that distinguishes this patent's monitoring method. The infringement analysis will turn on whether Sandoz's instructions and programs induce physicians to perform this specific act upon a change in a patient's antibody status.
- Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The patent links the entire monitoring and discontinuing process to improving safety, suggesting that any risk-based decision to stop treatment prompted by new antibody data falls within the claim's scope '845 Patent, col. 3:32-35
- Evidence for a Narrower Interpretation: The claim requires "discontinuing...in the presence of seroconversion and/or an increasing titer." Sandoz will likely argue its label instructs withholding treatment based on clinical "symptoms suggestive of PML" Compl. ¶162, not just on a change in antibody titer alone. This suggests a potential mismatch between the specific trigger for action in the claim versus the accused instructions.
VI. Other Allegations
- Indirect Infringement: The complaint's theory of infringement is based entirely on inducement. It alleges Sandoz, through its Tyruko product label, REMS program, and the Tyruko JCV Testing Program, actively and intentionally encourages and instructs healthcare professionals and patients to perform the steps of the patented methods, thereby inducing infringement of both the '245 and '845 patents (Compl. ¶131; Compl. ¶132; Compl. ¶133; Compl. ¶134, Compl. ¶158).
- Willful Infringement: Willfulness is alleged for both patents. The complaint asserts that Sandoz had pre-suit knowledge of the patents because Biogen provided its list of asserted patents, including the '245 and '845 patents, to Sandoz on August 26, 2022, as part of the BPCIA patent exchange Compl. ¶122 The complaint alleges Sandoz has known its activities would cause infringement or was willfully blind to that fact Compl. ¶¶133, 157
VII. Analyst's Conclusion: Key Questions for the Case
The resolution of this case will likely depend on the court's interpretation of several key issues:
- A central question will be one of inducement versus information: Do the Tyruko product label, REMS program, and associated testing services constitute active instruction and encouragement for physicians to perform the patented methods, or do they merely provide information that physicians use to exercise their own independent medical judgment? The court's decision on this issue will be critical for the indirect infringement analysis.
- A key evidentiary question for the '845 patent will concern the trigger for discontinuation: Does the accused Tyruko label, which instructs withholding treatment upon "the first sign or symptom suggestive of PML," induce infringement of a claim requiring discontinuation "in the presence of seroconversion and/or an increasing titer" of antibodies? The outcome may depend on whether a change in antibody status alone is considered a sufficient trigger under the claim, and whether the accused label instructs action based on that trigger.
- A third issue will be one of claim definiteness and function: The court may need to determine if the limitation "improves the safety of the natalizumab treatment," present in both asserted patents, is a definite and limiting claim element or an unenforceable statement of intended result. This will affect how Biogen must prove infringement and how Sandoz may challenge the claims' validity.
Analysis metadata
Loading Amended Complaint
Suggested improvements